<HashMap><database>biostudies-literature</database><scores/><additional><submitter>Tay RE</submitter><funding>Massachusetts Institute of Technology</funding><funding>Dr. Miriam and Sheldon G. Adelson Medical Research Foundation</funding><funding>Dana-Farber/Harvard Cancer Center</funding><funding>NCI NIH HHS</funding><funding>A*STAR</funding><funding>National Institutes of Health</funding><funding>NIAMS NIH HHS</funding><pagination>e20191453</pagination><full_dataset_link>https://www.ebi.ac.uk/biostudies/studies/S-EPMC7336313</full_dataset_link><repository>biostudies-literature</repository><omics_type>Unknown</omics_type><volume>217(7)</volume><pubmed_abstract>Cytotoxic T cells play a key role in adaptive immunity by killing infected or cancerous cells. While the transcriptional control of CD8 T cell differentiation and effector function following T cell activation has been extensively studied, little is known about epigenetic regulation of these processes. Here we show that the histone deacetylase HDAC3 inhibits CD8 T cell cytotoxicity early during activation and is required for persistence of activated CD8 T cells following resolution of an acute infection. Mechanistically, HDAC3 inhibits gene programs associated with cytotoxicity and effector differentiation of CD8 T cells including genes encoding essential cytotoxicity proteins and key transcription factors. These data identify HDAC3 as an epigenetic regulator of the CD8 T cell cytotoxicity </pubmed_abstract><journal>The Journal of experimental medicine</journal><pubmed_title>Hdac3 is an epigenetic inhibitor of the cytotoxicity program in CD8 T cells.</pubmed_title><pmcid>PMC7336313</pmcid><funding_grant_id>P01 CA163222</funding_grant_id><funding_grant_id>NCI R01 CA238039</funding_grant_id><funding_grant_id>R01 AR043369</funding_grant_id><funding_grant_id>R01 AR043369-19</funding_grant_id><funding_grant_id>R01 CA222871</funding_grant_id><funding_grant_id>R01 CA238039</funding_grant_id><funding_grant_id>R01 AR072304</funding_grant_id><pubmed_authors>Tay RE</pubmed_authors><pubmed_authors>Wucherpfennig KW</pubmed_authors><pubmed_authors>Long HW</pubmed_authors><pubmed_authors>Cejas P</pubmed_authors><pubmed_authors>Xie Y</pubmed_authors><pubmed_authors>Weng QY</pubmed_authors><pubmed_authors>Brown M</pubmed_authors><pubmed_authors>Olawoyin O</pubmed_authors><pubmed_authors>Fisher DE</pubmed_authors><pubmed_authors>Ito Y</pubmed_authors><pubmed_authors>Kim HJ</pubmed_authors><pubmed_authors>Meyer CA</pubmed_authors></additional><is_claimable>false</is_claimable><name>Hdac3 is an epigenetic inhibitor of the cytotoxicity program in CD8 T cells.</name><description>Cytotoxic T cells play a key role in adaptive immunity by killing infected or cancerous cells. While the transcriptional control of CD8 T cell differentiation and effector function following T cell activation has been extensively studied, little is known about epigenetic regulation of these processes. Here we show that the histone deacetylase HDAC3 inhibits CD8 T cell cytotoxicity early during activation and is required for persistence of activated CD8 T cells following resolution of an acute infection. Mechanistically, HDAC3 inhibits gene programs associated with cytotoxicity and effector differentiation of CD8 T cells including genes encoding essential cytotoxicity proteins and key transcription factors. These data identify HDAC3 as an epigenetic regulator of the CD8 T cell cytotoxicity </description><dates><release>2020-01-01T00:00:00Z</release><publication>2020 Jul</publication><modification>2026-04-18T03:07:44.76Z</modification><creation>2026-04-18T03:06:29.515Z</creation></dates><accession>S-EPMC7336313</accession><cross_references><pubmed>32374402</pubmed><doi>10.1084/jem.20191453</doi></cross_references></HashMap>